Sequencing of NOTCH1 gene in an Italian population with bicuspid aortic valve: Preliminary results from the GISSI OUTLIERS VAR study.


Journal

Gene
ISSN: 1879-0038
Titre abrégé: Gene
Pays: Netherlands
ID NLM: 7706761

Informations de publication

Date de publication:
05 Oct 2019
Historique:
received: 22 03 2019
revised: 13 06 2019
accepted: 08 07 2019
pubmed: 23 7 2019
medline: 28 8 2019
entrez: 23 7 2019
Statut: ppublish

Résumé

Bicuspid aortic valve (BAV) formation is genetically determined, with reduced penetrance and variable expressivity. NOTCH1 is a proven candidate gene and its mutations have been found in familial and sporadic cases of BAV. 66 BAV patients from the GISSI VAR study were genotyped for the NOTCH1 gene. We identified 63 variants, in heterozygous and homozygous states. Fifty-two are common polymorphisms present in almost all patients. Eleven variants are new and never yet reported: two are non-synonymous substitutions, Gly540Asp in exon 10 and Glu851Gln in exon 16; one is in the 3'UTR region and seven in introns, one corresponds to a T allele insertion in intron 27. We selected four statistically noteworthy and seven new variants identified in six BAV patients and correlated them with clinical and demographic variables and with imaging and histological parameters. Preliminary data show that four were BAV patients with isolated stenosis in patients over 60 aged. These variants may correlate with a later need for surgery for the presence of stenosis and not aortic valve regurgitation or ascending aortic aneurysm. Completing the genotyping of 62 BAV patients we found 11 new variants in the NOTCH1 gene never yet reported. These findings confirm that the identification of new, clinically remarkable biomarkers for BAV requires a deeper genetic understanding of the NOTCH1 gene variants, which could be targeted by future diagnostic and therapeutic strategies.

Sections du résumé

BACKGROUND BACKGROUND
Bicuspid aortic valve (BAV) formation is genetically determined, with reduced penetrance and variable expressivity. NOTCH1 is a proven candidate gene and its mutations have been found in familial and sporadic cases of BAV.
METHODS METHODS
66 BAV patients from the GISSI VAR study were genotyped for the NOTCH1 gene.
RESULTS RESULTS
We identified 63 variants, in heterozygous and homozygous states. Fifty-two are common polymorphisms present in almost all patients. Eleven variants are new and never yet reported: two are non-synonymous substitutions, Gly540Asp in exon 10 and Glu851Gln in exon 16; one is in the 3'UTR region and seven in introns, one corresponds to a T allele insertion in intron 27. We selected four statistically noteworthy and seven new variants identified in six BAV patients and correlated them with clinical and demographic variables and with imaging and histological parameters. Preliminary data show that four were BAV patients with isolated stenosis in patients over 60 aged. These variants may correlate with a later need for surgery for the presence of stenosis and not aortic valve regurgitation or ascending aortic aneurysm.
CONCLUSIONS CONCLUSIONS
Completing the genotyping of 62 BAV patients we found 11 new variants in the NOTCH1 gene never yet reported. These findings confirm that the identification of new, clinically remarkable biomarkers for BAV requires a deeper genetic understanding of the NOTCH1 gene variants, which could be targeted by future diagnostic and therapeutic strategies.

Identifiants

pubmed: 31330235
pii: S0378-1119(19)30620-1
doi: 10.1016/j.gene.2019.143970
pii:
doi:

Substances chimiques

NOTCH1 protein, human 0
Receptor, Notch1 0

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

143970

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Silvana Pileggi (S)

Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy. Electronic address: silvana.pileggi@marionegri.it.

Benedetta De Chiara (B)

Cardiology IV, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy; School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

Michela Magnoli (M)

Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

Maria Grazia Franzosi (MG)

Department of Cardiovascular Research, IRCCS Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.

Bruno Merlanti (B)

Cardiac Surgery, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy.

Francesca Bianchini (F)

ANMCO Research Center, Florence.

Antonella Moreo (A)

Cardiology IV, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy.

Gabriella Romeo (G)

Department of Cardiac, Vascular and Thoracic Sciences, University of Padua, Padua.

Claudio Francesco Russo (CF)

Cardiac Surgery, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy.

Stefania Rizzo (S)

Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua.

Cristina Basso (C)

Cardiovascular Pathology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua.

Luigi Martinelli (L)

Cardiothoracic Surgery, ICLAS-Istituto Clinico Ligure Alta Specialità, Rapallo.

Attilio Maseri (A)

Heart Care Foundation, Florence.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH